SAN MATEO, Calif., May 10, 2011 (GLOBE NEWSWIRE) -- Talon Therapeutics, Inc. (OTCBB:TLON) today announced the initiation of a Phase 3 Study of Marqibo (vincristine sulfate liposomes injection) in elderly patients with newly diagnosed aggressive Non-Hodgkin’s Lymphoma to be conducted by the German High-Grade Non-Hodgkin’s Lymphoma Study Group (DSHNHL).
